{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:42:05Z","timestamp":1788990125232,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003382","name":"Core Research for Evolutional Science and Technology","doi-asserted-by":"publisher","award":["JPMJCR15G1"],"award-info":[{"award-number":["JPMJCR15G1"]}],"id":[{"id":"10.13039\/501100003382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H05657"],"award-info":[{"award-number":["19H05657"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02716"],"award-info":[{"award-number":["21H02716"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22J14149"],"award-info":[{"award-number":["22J14149"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21am0401009"],"award-info":[{"award-number":["JP21am0401009"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21am0401009"],"award-info":[{"award-number":["JP21am0401009"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21gm6210005"],"award-info":[{"award-number":["JP21gm6210005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008880","name":"Kanae Foundation for the Promotion of Medical Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm Regener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is characterized by chronic inflammation and resultant cartilage\/bone destruction because of aberrantly activated osteoclasts. Recently, novel treatments with several Janus kinase (JAK) inhibitors have been shown to successfully ameliorate arthritis-related inflammation and bone erosion, although their mechanisms of action for limiting bone destruction remain unclear. Here, we examined the effects of a JAK inhibitor on mature osteoclasts and their precursors by intravital multiphoton imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Inflammatory bone destruction was induced by local injection of lipopolysaccharides into transgenic mice carrying reporters for mature osteoclasts or their precursors. Mice were treated with the JAK inhibitor, ABT-317, which selectively inhibits the activation of JAK1, and then subjected to intravital imaging with multiphoton microscopy. We also used RNA sequencing (RNA-Seq) analysis to investigate the molecular mechanism underlying the effects of the JAK inhibitor on osteoclasts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The JAK inhibitor, ABT-317, suppressed bone resorption by blocking the function of mature osteoclasts and by targeting the migratory behaviors of osteoclast precursors to the bone surface. Further exhaustive RNA-Seq analysis demonstrated that\n                      <jats:italic>Ccr1<\/jats:italic>\n                      expression on osteoclast precursors was suppressed in the JAK inhibitor-treated mice; the CCR1 antagonist, J-113863, altered the migratory behaviors of osteoclast precursors, which led to the inhibition of bone destruction under inflammatory conditions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first study to determine the pharmacological actions by which a JAK inhibitor blocks bone destruction under inflammatory conditions; this inhibition is beneficial because of its dual effects on both mature osteoclasts and immature osteoclast precursors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41232-023-00268-4","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:02:40Z","timestamp":1677801760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["JAK inhibition ameliorates bone destruction by simultaneously targeting mature osteoclasts and their precursors"],"prefix":"10.1186","volume":"43","author":[{"given":"Shinya","family":"Yari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hotaka","family":"Shigyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Okuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Furusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Minoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-007X","authenticated-orcid":false,"given":"Masaru","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"268_CR1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205\u201319.","journal-title":"N Engl J Med"},{"key":"268_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/art.21548","volume":"54","author":"S \u00d8deg\u00e5rd","year":"2006","unstructured":"\u00d8deg\u00e5rd S, Landew\u00e9 R, van der Heijde D, et al. Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. Arthritis Rheum. 2006;54:68\u201375.","journal-title":"Arthritis Rheum"},{"key":"268_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5114\/reum.2018.75523","volume":"56","author":"M Ostrowska","year":"2018","unstructured":"Ostrowska M, Ma\u015bli\u0144ski W, Prochorec-Sobieszek M, et al. Cartilage and bone damage in rheumatoid arthritis. Reumatologia. 2018;56:111\u201320.","journal-title":"Reumatologia"},{"key":"268_CR4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrg1122","volume":"4","author":"SL Teitelbaum","year":"2003","unstructured":"Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4:638\u201349.","journal-title":"Nat Rev Genet"},{"key":"268_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337\u201342.","journal-title":"Nature"},{"key":"268_CR6","first-page":"943","volume":"152","author":"EM Gravallese","year":"1998","unstructured":"Gravallese EM, Harada Y, Wang JT, et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol. 1998;152:943\u201351.","journal-title":"Am J Pathol"},{"key":"268_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature07713","volume":"458","author":"M Ishii","year":"2009","unstructured":"Ishii M, Egen JG, Klauschen F, et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature. 2009;458:524\u20138.","journal-title":"Nature"},{"key":"268_CR8","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1084\/jem.20101474","volume":"207","author":"M Ishii","year":"2010","unstructured":"Ishii M, Kikuta J, Shimazu Y, et al. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med. 2010;207:2793\u20138.","journal-title":"J Exp Med"},{"key":"268_CR9","first-page":"866","volume":"123","author":"J Kikuta","year":"2013","unstructured":"Kikuta J, Wada Y, Kowada T, et al. Dynamic visualization of RANKL and Th17-mediated osteoclast function. J Clin Invest. 2013;123:866\u201373.","journal-title":"J Clin Invest"},{"key":"268_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nchembio.2096","volume":"12","author":"H Maeda","year":"2016","unstructured":"Maeda H, Kowada T, Kikuta J, et al. Real-time intravital imaging of pH variation associated with osteoclast activity. Nat Chem Biol. 2016;12:579\u201385.","journal-title":"Nat Chem Biol"},{"key":"268_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrd1109","volume":"2","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2:473\u201388.","journal-title":"Nat Rev Drug Discov"},{"key":"268_CR12","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320:1360\u201372.","journal-title":"JAMA"},{"key":"268_CR13","first-page":"1219","volume":"77","author":"Y Matsuura","year":"2018","unstructured":"Matsuura Y, Kikuta J, Kishi Y, et al. In vivo visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption. Ann Rheum Dis. 2018;77:1219\u201325.","journal-title":"Ann Rheum Dis"},{"key":"268_CR14","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/rheumatology\/keaa476","volume":"60","author":"D van der Heijde","year":"2021","unstructured":"van der Heijde D, Landew\u00e9 RBM, Wollenhaupt J, et al. Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies. Rheumatology. 2021;60:1708\u201316.","journal-title":"Rheumatology"},{"key":"268_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13075-020-02379-6","volume":"23","author":"P Emery","year":"2021","unstructured":"Emery P, Durez P, Hueber AJ, et al. Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review. Arthritis Res Ther. 2021;23:3.","journal-title":"Arthritis Res Ther"},{"issue":"61","key":"268_CR16","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1093\/rheumatology\/keab861","volume":"3","author":"CG Peterfy","year":"2022","unstructured":"Peterfy CG, Strand V, Friedman A, et al. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. Rheumatology. 2022;3(61):3246\u201356.","journal-title":"Rheumatology."},{"key":"268_CR17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019;78:1305\u201319.","journal-title":"Ann Rheum Dis"},{"key":"268_CR18","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","volume":"80","author":"B Combe","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80:848\u201358.","journal-title":"Ann Rheum Dis"},{"key":"268_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","volume":"80","author":"R Westhovens","year":"2021","unstructured":"Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80:727\u201338.","journal-title":"Ann Rheum Dis"},{"key":"268_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","volume":"5","author":"K Yamaoka","year":"2004","unstructured":"Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol. 2004;5:253.","journal-title":"Genome Biol"},{"key":"268_CR21","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16:843\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"268_CR22","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1128\/MCB.20.11.4106-4114.2000","volume":"20","author":"S Jung","year":"2000","unstructured":"Jung S, Aliberti J, Graemmel P, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20:4106\u201314.","journal-title":"Mol Cell Biol"},{"key":"268_CR23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41467-017-02541-w","volume":"9","author":"M Furuya","year":"2018","unstructured":"Furuya M, Kikuta J, Fujimori S, et al. Direct cell-cell contact between mature osteoblasts and osteoclasts dynamically controls their functions in vivo. Nat Commun. 2018;9:300.","journal-title":"Nat Commun"},{"key":"268_CR24","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1093\/nar\/gkx064","volume":"45","author":"KK Nyati","year":"2017","unstructured":"Nyati KK, Masuda K, Zaman MM, et al. TLR4-induced NF-\u03baB and MAPK signaling regulate the IL-6 mRNA stabilizing protein Arid5a. Nucleic Acids Res. 2017;45:2687\u2013703.","journal-title":"Nucleic Acids Res"},{"key":"268_CR25","doi-asserted-by":"crossref","unstructured":"Hou GQ, Guo C, Song GH et al. Lipopolysaccharide (LPS) promotes osteoclast differentiation and activation by enhancing the MAPK pathway and COX-2 expression in RAW264.7 cells. Int J Mol Med. 2013;32:503\u201310.","DOI":"10.3892\/ijmm.2013.1406"},{"key":"268_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12865-021-00409-9","volume":"22","author":"MS AlQranei","year":"2021","unstructured":"AlQranei MS, Senbanjo LT, Aljohani H, et al. Lipopolysaccharide- TLR-4 axis regulates osteoclastogenesis independent of RANKL\/RANK signaling. BMC Immunol. 2021;22:23.","journal-title":"BMC Immunol"},{"key":"268_CR27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nri2634","volume":"9","author":"R Medzhitov","year":"2009","unstructured":"Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol. 2009;9:692\u2013703.","journal-title":"Nat Rev Immunol"},{"key":"268_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.4049\/jimmunol.1201345","volume":"190","author":"M Kotani","year":"2013","unstructured":"Kotani M, Kikuta J, Klauschen F, et al. Systemic circulation and bone recruitment of osteoclast precursors tracked by using fluorescent imaging techniques. J Immunol. 2013;190:605\u201312.","journal-title":"J Immunol"},{"key":"268_CR29","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.4049\/jimmunol.0803627","volume":"183","author":"K Koizumi","year":"2009","unstructured":"Koizumi K, Saitoh Y, Minami T, et al. Role of CX3CL1\/fractalkine in osteoclast differentiation and bone resorption. J Immunol. 2009;183:7825\u201331.","journal-title":"J Immunol"},{"key":"268_CR30","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1073\/pnas.1218799110","volume":"110","author":"J Kikuta","year":"2013","unstructured":"Kikuta J, Kawamura S, Okiji F, et al. Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc Natl Acad Sci USA. 2013;110:7009\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"268_CR31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","volume":"25","author":"A Mantovani","year":"2004","unstructured":"Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677\u201386.","journal-title":"Trends Immunol"},{"key":"268_CR32","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1359\/jbmr.040910","volume":"19","author":"X Yu","year":"2004","unstructured":"Yu X, Huang Y, Collin-Osdoby P, et al. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res. 2004;19:2065\u201377.","journal-title":"J Bone Miner Res"},{"key":"268_CR33","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201846255","volume":"19","author":"S Oki","year":"2018","unstructured":"Oki S, Ohta T, Shioi G, et al. ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data. EMBO Rep. 2018;19: e46255.","journal-title":"EMBO Rep"},{"key":"268_CR34","doi-asserted-by":"publisher","first-page":"e14627","DOI":"10.14814\/phy2.14627","volume":"8","author":"K Makitani","year":"2020","unstructured":"Makitani K, Ogo N, Asai A. STX-0119, a novel STAT3 dimerization inhibitor, prevents fibrotic gene expression in a mouse model of kidney fibrosis by regulating Cxcr4 and Ccr1 expression. Physiol Rep. 2020;8:e14627.","journal-title":"Physiol Rep"},{"key":"268_CR35","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1002\/art.34649","volume":"64","author":"TP LaBranche","year":"2012","unstructured":"LaBranche TP, Jesson MI, Radi ZA, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012;64:3531\u201342.","journal-title":"Arthritis Rheum"},{"key":"268_CR36","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1038\/s41467-017-02368-5","volume":"8","author":"JW Lee","year":"2017","unstructured":"Lee JW, Hoshino A, Inoue K, et al. The HIV co-receptor CCR5 regulates osteoclast function. Nat Commun. 2017;8:2226.","journal-title":"Nat Commun"},{"key":"268_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.38218","volume":"66","author":"K Yokota","year":"2014","unstructured":"Yokota K, Sato K, Miyazaki T, et al. Combination of tumor necrosis factor \u03b1 and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheumatol. 2014;66:121\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"268_CR38","doi-asserted-by":"publisher","first-page":"28826","DOI":"10.1074\/jbc.M109.099424","volume":"285","author":"A Hoshino","year":"2010","unstructured":"Hoshino A, Iimura T, Ueha S, et al. Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts. J Biol Chem. 2010;285:28826\u201337.","journal-title":"J Biol Chem"}],"container-title":["Inflammation and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-023-00268-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41232-023-00268-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-023-00268-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:04:28Z","timestamp":1677801868000},"score":1,"resource":{"primary":{"URL":"https:\/\/inflammregen.biomedcentral.com\/articles\/10.1186\/s41232-023-00268-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["268"],"URL":"https:\/\/doi.org\/10.1186\/s41232-023-00268-4","relation":{},"ISSN":["1880-8190"],"issn-type":[{"value":"1880-8190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y. F. is a full-time employee of AbbVie GK. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}